Shanghai, November 23, 2024 /PR Newswire/ -- November is International Lung Cancer Awareness Month. To enhance society's awareness and attention to lung diseases, the "Love Your Lungs Cycling, You and I Together" 2024 Health Cycling Public Welfare Event, organized by Henlius and supported by the Shanghai Fosun Public Welfare Fund and Fosun Pharma, was successfully held in Shanghai on November 23. The event invited more than a hundred participants including medical staff, media professionals, cycling enthusiasts, and volunteer employees. Through this green and healthy activity, it integrated health science popularization knowledge, collectively calling on the public to pay attention to lung health, advocate a healthy lifestyle, and actively establish the health concept of loving and protecting the lungs. Guests attending the event included Professor Gao Guanghui from the Oncology Department of Shanghai Pulmonary Hospital affiliated with Tongji University, Li Haifeng, Chairman of the Shanghai Fosun Public Welfare Fund, Zhang Wenjie, Executive President of Fosun Pharma and Chairman of Henlius, and Guo Xinjun, Senior Vice President of Henlius.

Focus on lung cancer prevention and treatment, safeguard respiratory health.

Respiratory diseases are a public health issue threatening the health of residents in China, with the total number of patients exceeding 100 million. Among them, the annual incidence of lung cancer reaches 1.0606 million cases, and the number of deaths is 0.733 million, ranking first among all types of cancer. To effectively address this challenge and implement the "Health China 2030 Planning Outline", it is necessary to further raise public awareness of lung cancer, vigorously promote the concept of early screening, early diagnosis, and early treatment, while also actively advocating for healthy lifestyles.

The special guest for this event, Professor Gao Guanghui from the Oncology Department of Shanghai Pulmonary Hospital affiliated with Tongji University, stated: "Scientific prevention and treatment of lung diseases, including lung cancer, requires protecting lung function. Aerobic exercise can strengthen the respiratory system and help improve lung function." He also emphasized that bad habits like smoking have become the main threat to residents' health, and advocating for healthy lifestyles while strengthening the prevention and control of risk factors is especially important. Engaging in public welfare activities can effectively enhance public awareness of diseases, encourage people to actively participate in health management, and has positive significance for establishing a long-term mechanism for preventing and treating lung cancer.

Multiple parties are working together to promote ‘lung’ health.

This event closely combines disease popularization with cycling, aimed at raising the deep attention of society to lung health. The cycling route starts and ends at the Henlius Songjiang Base (II), covering a total of 24 kilometers, with several interactive checkpoints set up along the way. The content widely covers basic knowledge of lung health, lung cancer prevention and treatment, and patient care, helping to enhance public health literacy and strengthen the q&m dental awareness of cancer prevention. Additionally, the event attracted active participation from enterprises, charitable foundations, and sports communities from multiple fields, forming a strong social synergy and laying a solid foundation for establishing a collaborative cancer prevention system for all.

Zhang Wenjie, Executive President of Fosun Pharma and Chairman of Henlius, stated: "The company always adheres to the philosophy of 'patient-centered', deeply engages in the field of major diseases such as lung cancer, and is committed to providing innovative treatment solutions. This 2024 Health Cycling Charity Event aims to call on the public to protect lung health through cycling and promotes the overall level of lung cancer prevention and treatment, contributing to the construction of health china and realizing a new future of health for all."

Li Haifeng, Chairman of the Shanghai Fosun Public Welfare Foundation, stated: "The Fosun Foundation actively responds to the national health strategy, aims to promote grassroots medical standards, and has long-term partnerships with public welfare partners like Henlius to carry out a variety of popular science projects. This event not only stimulated the attention of all sectors of society to lung health but also advocated for everyone to maintain healthy living habits, exploring new pathways for the vigorous development of the medical and health sector."

As the organizer and initiator of this event, henlius will continue to leverage its innovative advantages in the lung cancer field to improve patient survival benefits, contribute to changing the treatment landscape for lung cancer, and promote the prevention and treatment of major diseases such as lung cancer. At the same time, the company will actively practice the mission of health china, fulfill its corporate social responsibility in areas such as science popularization and education, empowering grassroots medical care, and caring for patients, contributing more to the development of social medical undertakings.

About Henlius

Henlius (2696.HK) is an international innovative biopharmaceutical company committed to providing affordable high-quality biopharmaceuticals for global patients. Its products cover fields such as oncology, autoimmune diseases, and ophthalmic diseases, with 6 products approved for market in China, 3 products approved for international markets, 24 approved indications, and 4 listing applications accepted by the National Medical Products Administration of China, the FDA of the USA, and the EMA of Europe. Since its establishment in 2010, Henlius has built an integrated biopharmaceutical platform, with efficient and innovative core capabilities spanning the entire industry chain from R&D, production to commercial operation. The company has established a comprehensive and efficient global innovation center, producing and controlling quality in accordance with international standards for Good Manufacturing Practices (GMP), continuously solidifying its integrated comprehensive production platform. Among these, the company's commercial production bases have successively obtained GMP certification from China, the EU, and the USA.

Henlius has proactively laid out a diversified and high-quality product pipeline covering over 50 molecules, and is comprehensively promoting the tumor immunity combination therapy based on its self-developed anti-PD-1 monoclonal antibody H drug Hansuzhuang. To date, the company's approved products include China's first biosimilar Hanlikang (rituximab), the self-developed monoclonal antibody biosimilar Hanquyou (trastuzumab) approved in China, the USA, and Europe (US trade name: HERCESSI, EU trade name: Zercepac), Handayuan (adalimumab), Hanbeitai (bevacizumab), and Hannajia (neratinib). Additionally, the innovative product Hansuzhuang (sruvilumab) has been approved for the treatment of microsatellite instability-high (MSI-H) solid tumors, squamous non-small cell lung cancer, extensive small cell lung cancer, and esophageal squamous cell carcinoma, and has become the world's first anti-PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer. The company is also concurrently conducting over 30 clinical trials on 16 products globally, with licensing agreements covering major biopharmaceutical markets in Europe and the USA as well as numerous emerging markets.